Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
KRKeros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS)

NASDAQ Global Market · Currency in USD
$11.28 ▼ -0.07 (-0.62%)
At close: Oct 23, 4:00 PM ET. Market closed.
$11.28 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$11.35
Open
$11.08
Day's Range
$10.92 – $11.32
52 Week Range
$9.69 – $22.55
Volume
120,901
Avg. Volume
219,587
Market Cap
$223.65M
Beta (5Y Monthly)
1.02
PE Ratio (TTM)
--
EPS (TTM)
-$4.20
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$20.33

Profile: Keros Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
92
CEO
Jasbir S. Seehra

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.96 · Revenue est. $14.76M
DateEst.Actual
Aug 3, 2026-$1.34-$1.45Miss
May 14, 2026-$0.92-$1.21Miss
Mar 4, 2026-$0.49-$0.86Miss
Nov 5, 2025-$1.11-$0.18Beat
Aug 6, 2025-$1.14-$0.76Beat
May 6, 2025-$0.01$3.62Beat

Analyst view

Consensus price target
$20.33 ▲ +80.2%
Range $18.00 – $23.00
Rating: Buy
Buy 59% · Hold 41% · Sell 0%

Get free alerts on KROS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.